Sandra Jablonski

Title: The Innovative Contributions of Sandra Jablonski

Introduction

Sandra Jablonski is a prominent inventor based in Silver Spring, MD (US). She has made significant strides in the field of cancer treatment, holding 2 patents that focus on innovative methods for combating cancerous tumors.

Latest Patents

Her latest patents involve treating cancer with a cholecystokinin (CCK) receptor inhibitor and an immune checkpoint inhibitor. These patents detail methods for treating a CCK receptor-expressing cancerous tumor in a subject. The methods comprise administering an effective amount of a CCK receptor inhibitor and an immune checkpoint inhibitor. The CCK receptor inhibitor targets one or more CCK receptors, including CCK-A, CCK-B, and CCK-C receptors. The immune checkpoint inhibitor can be a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.

Career Highlights

Sandra Jablonski is affiliated with Georgetown University, where she continues her research and development in cancer therapies. Her work has garnered attention for its potential to improve treatment outcomes for patients with specific types of cancer.

Collaborations

Some of her notable coworkers include Jill P Smith and Sandeep Nadella, who contribute to her research efforts and collaborative projects.

Conclusion

Sandra Jablonski's innovative work in cancer treatment exemplifies the impact of dedicated research and collaboration in the medical field. Her contributions are paving the way for new therapeutic approaches that could benefit many patients in the future.